Elanco Earnings Call Highlights Innovation-Led Growth Path

Elanco Animal Health ((ELAN)) has held its Q4 earnings call. Read on for the main highlights of the call.

Elanco Animal Health’s latest earnings call struck an optimistic tone, highlighting strong product launches, accelerating innovation revenue, and steady deleveraging. Management acknowledged near-term headwinds from taxes, inflation, and manufacturing ramp-up, but framed them as manageable bumps on a path toward higher 2026 earnings and margin expansion.

Robust Q4 and Full-Year Revenue Growth

Elanco reported Q4 2025 organic constant-currency revenue growth of 9%, with reported revenue of $1.14 billion, up 12% year over year. For the full year, organic growth reached 7% and reported revenue rose 6% to $4.72 billion, underscoring solid demand across both pet and farm animal segments.

Innovation Engine Outperforms, 2026 Outlook Raised

Innovation revenue reached $892 million in 2025, with the largest quarterly contribution coming in Q4, underscoring the strength of recent launches. On the back of this performance, Elanco raised its 2026 innovation outlook to $1.15 billion, implying at least $250 million in incremental growth versus 2025.

Credelio Quattro Drives Blockbuster Pet Momentum

Credelio Quattro was described as the fastest blockbuster in the company’s history, benefiting from a major U.S. broad-spectrum endectocide market that grew about 30% year over year. The product has penetrated roughly one-third of clinics, is showing strong Puppy Index metrics, and is lifting sales across Elanco’s broader portfolio.

ZENRELIA Gains Share Across Key Dermatology Markets

ZENRELIA continued its strong launch trajectory, achieving double-digit JAK inhibitor market share in several international markets, including about 40% in Brazil and over 30% in Japan. In the U.S., the product has reached roughly 50% clinic penetration with reorder rates above 80% and is gaining early traction in Europe, the U.K., and Australia.

Additional Launches and OTC Strength Support Growth

Bifrenna secured regulatory approval at year-end and is set for a phased 2026 launch, adding another biologic growth driver. Over-the-counter AdTab sales rose more than 50%, becoming the number-one oral OTC product in Europe, while Experior grew 35% in Q4 and surpassed $200 million in 2025, nearly doubling year over year.

Balanced Growth in Farm and Pet Health

U.S. farm animal revenue grew 17% in Q4, while U.S. pet health increased 10%, reflecting broad-based strength in core markets. Internationally, pet health rose 8% and farm animal 4% on an organic constant-currency basis, signaling healthy global demand despite regional variability.

EBITDA, EPS, and Deleveraging Progress

Adjusted EBITDA reached $189 million in Q4, up 7% year over year, and $901 million for the full year, signaling improved profitability. Full-year adjusted EPS rose to $0.94 from $0.91 in 2024, while net leverage fell to 3.6x, with management reiterating a path toward 3.1–3.3x in 2026 and below 3x in 2027.

Productivity Initiatives Underpin Margin Ambitions

The Elanco Ascend productivity program and related restructuring are underway, targeting roughly $25 million of savings in 2026. Management emphasized that these efficiencies will help fund launches and R&D while supporting gross margin expansion and sustained earnings growth.

Strategic M&A and a Deepening Pipeline

Elanco signed an agreement to acquire AHV International, a Dutch farm-animal innovator, to bolster its dairy portfolio and solutions set. The R&D engine is focused on delivering five to six potential blockbuster approvals by 2031, with the so-called Big Six products expected to double between 2025 and 2028.

Tax-Driven EPS Pressure in Q4

Despite operational momentum, Q4 adjusted EPS slipped 7% year over year to $0.13, reflecting a higher tax burden. The full-year effective tax rate increased to 21.8%, up roughly 370 basis points, with timing-related factors weighing on quarterly earnings.

Operating Cash Flow Softness in the Quarter

Cash from operations declined to $108 million in Q4, compared with $177 million a year earlier, due largely to expected cash tax payments tied to a prior divestiture. Management noted that working capital improvements partially offset this drag, suggesting the cash impact was more timing-related than structural.

Inflation and Inventory Costs Pressure Margins

Adjusted gross margin for 2025 held flat year over year at 54.9%, as inflation and higher inventory costs flowed through the P&L. The company expects gross margin to decline in the first half of 2026 before improving in the back half, as pricing, mix, and productivity gains begin to offset these pressures.

Higher Interest Costs After Swap Benefit Roll-Off

Quarterly interest expense rose 2% to $47 million as the benefit from a favorable interest rate swap amortization expired in 2025. The roll-off of this tailwind is expected to keep interest costs higher versus the prior favorable period, modestly constraining EPS leverage from the balance sheet.

Manufacturing Constraints for mAb Launches

Management highlighted manufacturing ramp constraints for monoclonal antibody products, particularly for Bifrenna, which will roll out in phases as bioreactor capacity scales up. While this may moderate the near-term launch cadence, the company framed it as an execution challenge rather than a demand issue.

Competitive and Market Headwinds Acknowledged

Guidance embeds ongoing competition from generics and new entrants across key categories, prompting a need for pricing discipline and agile commercial responses. These dynamics could temper near-term growth, but management pointed to portfolio breadth and innovation as buffers against share erosion.

Leverage Remains Elevated but Trending Lower

Net debt ended the year at about $3.2 billion, translating to 3.6x net leverage, which remains high but moving in the right direction. Elanco reiterated its plan to reduce leverage to 3.1–3.3x by year-end 2026 and below 3x in 2027, even before factoring in longer-term goals.

Conservative 2026 Outlook Versus Recent Momentum

Analysts questioned whether the 2026 guidance was conservative given strong late-2025 trends, pricing acceleration, and product ramps. Management stuck to a framework consistent with its long-term algorithm, suggesting the outlook reflects prudent assumptions in light of macro and competitive uncertainties.

Forward-Looking Guidance and 2026 Roadmap

For 2026, Elanco projects organic constant-currency revenue growth of 4%–6%, implying revenue of $4.95–$5.02 billion, with adjusted EBITDA of $955–$985 million and adjusted EPS of $1.00–$1.06. The company expects about 40 basis points of gross-margin expansion, around 7% OpEx growth, innovation revenue of $1.15 billion, roughly $25 million in productivity savings, and a step down in net leverage to 3.1–3.3x by year-end.

Elanco’s earnings call painted a picture of a company leaning into innovation-led growth while methodically cleaning up its balance sheet. While higher taxes, inflation, and manufacturing constraints may weigh on near-term results, management’s focus on productivity, pipeline execution, and disciplined guidance suggests investors can expect steady, albeit measured, upside into 2026 and beyond.